secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0000950170-23-034113
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Acasti Pharma regains Nasdaq minimum bid price compliance after reverse split
-----------------------------------------------------------------------------

- Received Nasdaq notice on July 24, 2023 confirming compliance with Listing Rule 5550(a)(2).
- Compliance achieved through a 1-for-6 reverse share split effective July 10, 2023.
- Company continues trading on Nasdaq Capital Market under symbol ACST.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023034113/0000950170-23-034113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023034113/acst-20230724.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-034113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer